-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On the 27th, foreign media reported that the Wupperta region of Germany will become a vaccine production site within this year.
It is reported that the plant will be used to produce the active ingredients of the new crown vaccine and other biological agents.
In December of last year, WuXi Biologics announced that it would acquire Bayer Group's biological drug solution manufacturing plant in Wupperta at a price of 150 million euros to continue to expand its global production capacity.
At the beginning of last year, WuXi Biologics Germany purchased from Bayer the facilities and assets of its cGMP filling and manufacturing plant for biopharmaceutical preparations in Lihuaguxun, Germany.
Leave a message here